Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/ GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-ofaction studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.
Leishmania parasites cause a wide spectrum of human infections ranging from the life-threatening visceral disease to disfiguring mucosal and cutaneous forms. Leishmania spp. are obligate intracellular parasites of the vertebrate reticuloendothelial system, where they multiply as amastigotes within macrophage phagolysosomes; transmission is by blood-sucking sandflies, in which they proliferate as extracellular promastigotes.
Visceral leishmaniasis, resulting from infection with Leishmania donovani and L. infantum, causes 20,000-40,000 deaths annually according to the WHO (World Health Organization; http://www. who.int/leishmaniasis/en/), of which approximately 60% occur in India, Bangladesh and Nepal 1 . In 95% of cases, death can be prevented by timely and appropriate drug therapy 2 . However, current treatment options are far from ideal, with outcomes depending on several factors including geographical location, the immune status and other comorbidities of the patient, and the disease classification. None of the current front-line treatments for visceral leishmaniasis-amphotericin B (liposomal or deoxycholate formulations), miltefosine, paromomycin and antimonials-is ideal for use in resource-poor settings, owing to issues such as teratogenicity, cost, resistance and/or clinical relapse, prolonged treatment regimens and parenteral administration [3] [4] [5] . Thus, there is an urgent need for new treatment options for visceral leishmaniasis, particularly oral drugs. Unfortunately, there are currently, to our knowledge, no new therapeutics in clinical development and only a few in preclinical development. There is a paucity of well-validated molecular drug targets in Leishmania, and the molecular targets of the current clinical molecules are unknown. Recent studies 6 identified the proteasome as a promising therapeutic target for the treatment of visceral leishmaniasis as well as other kinetoplastid infections, and this currently represents the most robustly validated drug target that has been reported in these parasites. Furthermore, whole-cell (phenotypic) screening programs have been hindered by extremely low hit rates 7 .
Here, we report the discovery of a promising anti-leishmanial compound with a new mechanism of action.
Discovery
Previously, we reported the identification of a diaminothiazole series from a compound screen against Trypanosoma brucei GSK3 kinase (TbGSK3) 8 . During compound optimization, it became clear that the anti-trypanosomal activity of this series was driven, at least in part, by off-target activity. The early compounds showed activity against T. brucei bloodstream trypanosomes in viability assays, but showed little activity against L. donovani axenic amastigotes (for example, compound 1). Modification of the core structure, while retaining the functions of the hydrogen bond donor and acceptor, gave a bicyclic compound series ( Fig. 1 ), one of which (compound 2) showed very weak activity against L. donovani axenic amastigotes, but was inactive against the more clinically relevant intra-macrophage amastigotes. Appending a sulfonamide to the cyclohexyl ring resulted in compound 3, which was active against L. donovani amastigotes in both the axenic and intra-macrophage assays 9, 10 and selectively active against L. donovani compared to the THP-1 mammalian host cells used in the assay. Replacement of the iso-butyl substituent on the pyrazole ring with an aromatic substituent and the benzyl group on the sulfonamide with a trifluoropropyl substituent resulted in compound 4, which had marginally more activity. Notably, this compound demonstrated more than 70% parasite reduction in a mouse model of visceral leishmaniasis when dosed orally, providing proof of concept in an animal model for this series. Replacing the pyridyl group with a 2-methoxyphenyl and the trifluoropropyl group with an iso-butyl group gave our most potent compound 5, which had a half-maximum effective concentration (EC 50 ) value of 0.014 μM in the intra-macrophage assay. Compound 5 was metabolically unstable, although it demonstrated more than 95% parasite reduction when dosed in a hepatic cytochrome P450 Article reSeArcH reductase-null (HRN) mouse model of infection 11 . In addition, the solubility of compounds 4 and 5 was poor.
The 2-methoxyphenyl group of 5 was replaced by a morpholine (compound 6) to increase the polarity, increase the three-dimensional shape (sp 3 character) and reduce the number of aromatic rings. This was substituted with a 2-methyl group to reduce the planarity further, and the trifluoropropyl sulfonamide was re-introduced, to give the key compound 7 (also known as DDD853651 or GSK3186899) 12 . This compound was selected as our preclinical candidate, on the basis of the overall properties of the molecule (potency, efficacy in the mouse model, pharmacokinetics and safety profile).
Compound 7 was active against L. donovani in an intra-macrophage assay 9 with an EC 50 value of 1.4 μM (95% confidence interval 1.2-1.5 μM, n = 12), and showed good selectivity against mammalian THP-1 host cells (EC 50 value > 50 μM). This is not as potent as our reported data for amphotericin B (EC 50 value of 0.07 μM in the intra-macrophage assay), but is comparable to the clinically used drugs miltefosine and paromomycin (EC 50 values of 0.9 μM and 6.6 μM, respectively) 9 . Compound 7 was also active in our cidal axenic amastigote assay (EC 50 value of 0.1 μM; 95% confidence interval 0.06-0.170 μM, n = 4) 10 . At a concentration of 0.2 μM, compound 7 was cytocidal at 96 h; increasing the concentration to 1.8 μM reduced this time to 48 h (Extended Data Fig. 1 ). Compound 7 demonstrated a less than 10-fold variation in potency against a panel of Leishmania-derived lines. The compound was also more active in a panel of Leishmania lines using human peripheral blood mononuclear cells as the host cells (Extended Data Table 1) .
A balance between solubility in relevant physiological media (Extended Data Table 2 ) and in vitro potency proved key for the development of this series. Compound 7 was stable when incubated with liver microsomes or hepatocytes, predictive of good metabolic stability (Extended Data Table 3 ). The compound was orally bioavailable and showed a linearity of pharmacokinetics from 10 to 300 mg kg −1 in rats (Extended Data Table 4 ). In our mouse model of infection, the compound demonstrated comparable activity to the front-line drug miltefosine, reducing parasite levels by 99% when dosed orally twice Potencies against axenic amastigotes, intramacrophage amastigotes and against THP-1 cells are shown 9 ; data show the geometric mean of at least three independent replicates. In the cidal axenic assay, a higher cell density and improved detection limit is used compared to the axenic assay, allowing distinction between cytostatic and cytotoxic compounds 10 . HBA, hydrogen bond acceptor; HBD, hydrogen bond donor.
Article reSeArcH a day for 10 days at 25 mg kg −1 (Fig. 2 ). The efficacy of treatment was dependent on dose, frequency (twice a day better than once), and duration (10 days better than 5). The non-clinical safety data for compound 7 suggest a suitable therapeutic window for progression into regulatory preclinical studies. In vitro assays demonstrated that this compound does not markedly inhibit cytochrome P450 enzymes, mitigating a potential risk of problematic drug-drug interactions that is particularly relevant owing to the frequency of co-infections of visceral leishmaniasis and HIV 1 .
As the series was developed from a known protein kinase scaffold 13 , Kinobead technology was used to determine whether compound 7 inhibits human protein kinases 14 . These experiments indicated that compound 7 interacted with four human kinases-MAPK11, NLK, MAPK14 and CDK7-at concentrations within multiples of the predicted clinical dose ( Supplementary Table 1 ). However, the extent of inhibition of these human kinases is not sufficient to preclude clinical development of the molecule, and no marked inhibition of other human kinases was detected in the Kinobead assays. Non-GLP preclinical assessment of cardiovascular effects and genotoxicity did not reveal any issues that would prevent further development. In addition, there were no notable adverse effects in a rat seven-day repeat-dose oral toxicity study with respect to clinical chemistry and histopathology at all doses tested. Both the in vivo efficacy and safety profile of compound 7 support progression to definitive safety studies.
Mode of action studies
Determining the mode of action of new chemical series can greatly benefit drug discovery campaigns 15 . Because there is no blueprint to establish the mode of action of bioactive small molecules 16, 17 , several complementary methods were used. Representative pyrazolopyrimidine analogues (4, 5, 6 and 7) from the drug discovery program were used as chemical tools ( Fig. 1) , as was compound 8, in which the diaminocyclohexyl group was replaced by an aminopiperidine amide. These compounds showed very good activity correlation between the intra-macrophage, axenic amastigote and promastigote assays, giving us confidence to use the extracellular parasite forms (promastigote) for mode-of-action studies where it was not possible to use the intracellular forms (amastigote) (Supplementary Table 2 ).
As a first step towards identifying the target(s) of the leishmanocidal pyrazolopyrimidine series, structure-activity relationships were used to inform the design of analogues containing a polyethyleneglycol (PEG) linker (9, 11 and 12; Extended Data Fig. 2 ), which were then covalently attached to magnetic beads to allow for chemical proteomics. First, beads derivatized with compound 9 were used to pull-down proteins from SILAC (stable isotope labelling by amino acids in cell culture)labelled L. donovani promastigote lysates 18 in the presence ('light-labelled lysate') or absence ('heavy-labelled lysate') of 10 μM compound 10, a structurally related, bioactive derivative of compound 9 19 . After combining the bead eluates and performing proteomic analyses, proteins that bound specifically to the pyrazolopyrimidine pharmacophore could be distinguished from proteins that bound non-specifically to the beads by virtue of high heavy: light tryptic peptide isotope ratios. These experiments identified CRK12, CRK6, CYC9, CRK3, MPK9, CYC6 and a putative STE11-like protein kinase (LinJ.24.1500) as specific binders to the compound 9-derivatized beads (log 2 of heavy:light ratio > 2.8; 7-fold enrichment) ( Supplementary Fig. 5 and Supplementary Table 3 ). Second, pull-down experiments were conducted with beads derivatized with compounds 9, 11 or 12, followed by competition studies with compounds 5, 8 or 8, respectively. Adherent proteins were washed off the beads, digested with trypsin and labelled with isobaric tandem mass tags. Comparison of the labelled peptides derived from experiments, with and without competition, by liquid chromatography-tandem mass spectrometry identified proteins that are likely to bind specifically to the immobilized ligands. Potential candidates identified included CRK3, CRK6, CRK12, CYC3, CYC6, CYC9, MPK9 and MPK5 and several hypothetical proteins (Supplementary Fig. 6 and Supplementary  Table 4 ). We also investigated immobilizing the compound at an alternative position on the scaffold and this gave a similar binding profile (Supplementary Fig. 6 and Supplementary Table 4 ), further validating the approach. These results are consistent with previous studies that report that the pyrazolopyrimidine core binds to protein kinases 13, [20] [21] [22] .
The presence of cdc2-related kinases (CRK3, CRK6 and CRK12) and cyclins (CYC3, CYC6 and CYC9) in the initial target list led us to analyse the effects of pyrazolopyrimidines (5, 6, 7 and 8) on cell-cycle progression in L. donovani. Treatment resulted in an accumulation of cells in the G1 and in G2/M phases of the cell cycle, and a decrease in the proportion of cells in S phase ( Fig. 3a for compound 7 and Supplementary Fig. 9 for compounds 5, 6 and 8), suggesting arrests in the cell-cycle at G1/S and G2/M phases, consistent with a mode of action via CRK and/or CYC components.
Resistance was generated in L. donovani promastigotes against compounds 4 and 5. A single cloned parental cell line was divided into three individual cultures for each compound, and resistance was generated by exposing parasites to step-wise increasing the concentrations of the compounds. After resistance generation, each independently generated cell line was cloned and three individual clones for each compound (six in total) were selected for in-depth study. The resulting clones demonstrated more than 500-fold and 9-17-fold resistance to compounds 4 and 5, respectively (Extended Data Table 5 ). Resistance to both compounds was found to be stable over 50 days in culture in the absence of drug pressure and, notably, all clones showed cross-resistance to compounds 4 and 5, and 20-50-fold cross-resistance to compound 7. These data suggest our pyrazolopyrimidines share common mechanisms of resistance and most likely modes of action. Importantly, intracellular amastigotes, derived from the resistant promastigotes, were 8.5-fold and 5-fold resistant to compounds 5 and 7, respectively, compared to wild-type parasites (Extended Data Table 6 ), strongly suggesting that their mechanism(s) of action are the same in promastigote and intracellular amastigote stages of the parasite.
To gain further insight into the mechanism of action and potential target(s) of this pyrazolopyrimidine series, our six drug-resistant clones underwent whole-genome sequence analysis. A range of mutations, relative to parental clones, were found across the genome ( Supplementary  Table 5 ), including a long region with loss of heterozygosity on 31, 32 Article reSeArcH chromosome 9. In total, 75 sites were identified genome-wide that each had single base substitutions that resulted in a non-synonymous change in at least one clone (Supplementary Table 6 ). Most (65) of the non-synonymous substitutions consisted of derived clones losing a parental allele but amplifying the remaining allele. In five of the six resistant clones, a new heterozygous substitution was selected in a single gene of unknown function (LdBPK_251630) but most notably, in all six drug-resistant clones, a single homozygous non-synonymous substitution was found in CRK12 (LdBPK_090270), a gene within the long loss-of-heterozygosity region. This mutation changes Gly572 to Asp and falls within the region predicted to encode the catalytic domain of L. donovani CRK12. This suggests that CRK12 is the target of the pyrazolopyrimdines. Extensive variations in chromosomal copy numbers are common in Leishmania 23, 24 , and extra copies of chromosome 9, containing the CRK12 gene, were found in four out of six of the drug-resistant clones ( Supplementary Table 7 ). In addition, three of these four clones had extra copies of chromosome 32, containing the gene for CYC9. Previous studies in T. brucei have established that the partner cyclin of CRK12 is CYC9 25 . This suggests that CYC9 may be the cognate cyclin partner for L. donovani CRK12.
Target validation
To dissect the role of CRK12 and CYC9 in the mechanism of action and resistance of pyrazolopyrimidines, a series of protein overexpression studies were undertaken in L. donovani promastigotes. In all cases, overexpression of putative targets was confirmed by increased levels of transcripts in our transgenic cell lines relative to the wild-type cells, as determined by quantitative PCR (qPCR) ( Supplementary Table 8 ).
Counterintuitively, overexpression of wild-type CRK12 rendered the parasites approximately 3-fold more sensitive to compound 5 (Fig. 3b ). The overexpression of CYC9 alone had no effect on compound resistance, but co-overexpression of CYC9 and wild-type CRK12 rendered the transgenic parasites around 3-fold more resistant to compounds 5 and 7 ( Fig. 3c and Supplementary Table 8 ). Next, we looked at the mutated (Gly572 to Asp) version of CRK12 (CRK12(G572D)) identified in all of our drug-resistant clones. Overexpression of CRK12(G572D) rendered the parasites around 3.4-fold resistant to compound 5 ( Fig. 3d and Supplementary Table 8 ) and to the preclinical lead compound 7 ( Supplementary Table 8 ), while being equally sensitive to the unrelated nitroimidazole drug fexinidazole sulfone (Supplementary Table 9 ). Co-overexpression of CRK12(G572D) and CYC9 rendered the parasites 6-fold more resistant to compound 7 and 8-fold more resistant to compound 5. This shift in sensitivity is considerably greater than the 3.4-fold increased resistance observed with parasites overexpressing CRK12(G572D) alone (Fig. 3d) . Replacing a single copy of the CRK12 gene with a drug-selectable marker left parasites approximately 2-fold more susceptible to compound 5 than the wild-type cells ( Fig. 3e and Supplementary Fig. 10 ). We were unable to directly replace both endogenous copies of the CRK12 gene, except in the presence of an ectopic copy of the gene, suggesting that the CRK12 gene is essential for the growth and survival of L. donovani ( Supplementary Fig. 10 ).
Initially, CRK3 and CRK6 were identified as credible targets based on our collective proteomics datasets, as well as their established roles in kinetoplastid cell cycle regulation 26, 27 . However, wholegenome sequencing, qPCR ( Supplementary Fig. 8 ) and Southern blot ( Supplementary Fig. 7 ) analysis of resistant clones confirmed that mutations within, or amplification of, the CRK3 and CRK6 genes were not responsible for resistance to pyrazolopyrimidines. Direct modulation of CRK3 and CRK6 levels within L. donovani promastigotes, by generating overexpressing and single-gene knockout parasites, did not alter drug sensitivity (Supplementary Table 8 ). Overexpression of CRK3 and CRK6 in combination with their cognate cyclin partners CYC6 and CYC3 was not possible because co-overexpression proved toxic. Collectively, these data suggest that the primary mechanism of action of this compound series is unlikely to be via CRK3 or CRK6 inhibition.
Commonly, overexpression of the molecular target of a compound is accompanied by an increase in drug resistance. With this in mind, our collective data strongly suggest that the principal target of our pyrazolopyrimidine series is the CYC9-activated form of CRK12, such that overexpression of CRK12 and CYC9 together provides resistance. This hypothesis is also consistent with the amplification of both CRK12 and CYC9 in resistant parasites; as well as the identification of both proteins in our SILAC and Kinobead proteomic datasets. The fact that overexpression of CYC9 alone has no effect suggests that CYC9 is, to some extent, in excess over CRK12 and thus overexpression of CRK12(G572D) can provide (3-fold) resistance that is increased when additional CYC9 is co-expressed (8-fold). The 'hyper-sensitivity' of parasites overexpressing wild-type CRK12 alone to these compounds remains perplexing. One potential explanation is that wild-type CRK12 bound to a Article reSeArcH pyrazolopyrimidine in the absence of a CYC9 subunit is particularly toxic to the parasite. Alternatively, increased levels of CRK12 may well sequester other cyclins, thereby preventing their essential interactions with other CRKs. Further studies will be required to test these hypotheses.
Given that the compounds from this chemical series interacted with protein kinases, in particular CRK12, we used Kinobead technology 14, 28, 29 with axenic amastigote extracts to identify pyrazolopyrimidine-binders in the Leishmania kinome. These experiments were performed in the presence or absence of an excess of the soluble parent compound 5. All proteins captured by the beads were quantified by tandem mass tag (TMT) labelling of tryptic peptides followed by liquid chromatography-tandem mass spectrometry analysis 30 . CRK12, MPK9, CRK6 and CYC3 (Fig. 4a) were identified, consistent with the other experiments above. A dose-response experiment was performed in which compound 5 was added over a range of concentrations to establish a competition-binding curve and determine a half-maximal inhibition concentration (IC 50 ) value (Fig. 4b) . The IC 50 values obtained in these experiments represent a measure of target affinity, but are also affected by the affinity of the target for the bead-immobilized ligands. The latter effect can be deduced by determining the depletion of the target proteins by the beads, such that apparent dissociation constant (K d ) values can be determined that are largely independent from the bead ligand 30 . The apparent K d values were 1.4 nM for CRK12, 45 nM for MPK9, 58 nM for CYC3 and 97 nM for CRK6. These values are determined in physiological conditions (substrates, cyclins and ATP) and provide further compelling evidence that the principal target of this compound series is CRK12. Further pull-downs with a resin-bound pyrazolopyrimidine analogue (11) were conducted in parallel with the Kinobead experiments and returned broadly similar results (Fig. 4c, d) .
Collectively, our data provide strong evidence that CRK12 forms an important interaction with CYC9: (1) our studies indicate that overexpression of CYC9 together with CRK12 markedly increases resistance to our pyrazolopyrimidine compounds; (2) in several of our compoundresistant cell lines, additional copies of chromosome 32, containing the CYC9 gene, were found; (3) in the related organism T. brucei, CYC9 was confirmed as the partner cyclin for CRK12; and (4) in several chemical proteomics studies, CYC9 was identified as binding to immobilized compounds from our pyrazolopyrimidines alongside CRK12.
Modelling
A homology model was built for L. donovani CRK12 using the structure of human cyclin dependent kinase 9 (CDK9, Protein Data Bank (PDB) code 4BCF) as a template. (Notably, compound 7 showed an IC 50 value of greater than 20 μM against CDK9 in the Kinobead assay.) A combination of docking studies, molecular dynamics simulation and free-energy calculations indicated that the most likely binding mode is that shown in Fig. 5 (see Supplementary Information for discussion). With very few exceptions, the binding modes of protein kinase inhibitors are highly conserved across kinase family members; searching the protein database revealed a related 5-amino-pyrazolopyrimidine, which bound to ALK in a very similar fashion (PDB code 4Z55, ligand 4LO). In our proposed binding mode, the bicyclic scaffold interacts with the hinge residues establishing two hydrogen bonds between the sp 2 pyrimidine nitrogen in position 6 and the backbone NH of Ala566, and between the pyrazole NH in position 1 and the backbone carbonyl oxygen of Ala564 (Fig. 5b) . A third hydrogen bond is also established between the amino NH in position 5 and the backbone carbonyl oxygen of Ala566. The substituent in position 3 of the pyrazole ring is directed towards the ATP back-pocket interfacing with the gatekeeper residue (Phe563). This binding mode is consistent with the analogues 9, 11 and 12 retaining binding affinity, with the PEG linkers being attached to water-accessible parts of the core. The Gly572Asp mutation that causes resistance to the pyrazolopyrimidine series is located at the end of the hinge region, nine residues from the gatekeeper. In the Gly572Asp mutant, the negatively charged side chain of the aspartic acid is positioned in close contact to the oxygen atoms of the sulfonamide moiety, leading to an unfavourable electrostatic interaction.
Discussion
New oral drugs for visceral leishmaniasis, particularly those capable of treating ongoing outbreaks in East Africa, are urgently needed. Effective drugs will make a notable difference to treatment outcomes for this devastating parasitic disease. With the ultimate goal of elimination of visceral leishmaniasis, several treatment options will be required. We have identified a pyrazolopyrimidine series that shows the potential to treat visceral leishmaniasis. Our studies indicate that the principal mechanism of action of our pyrazolopyrimidine compounds is by the inhibition of CRK12, defining CRK12 as one of very few chemically Article reSeArcH validated drug targets in Leishmania. Furthermore, our data indicate that CYC9 is the definitive partner cyclin for CRK12. The physiological function(s) of CRK12 and CYC9 have yet to be determined and the availability of our inhibitory pyrazolopyrimidines should assist in probing this aspect of parasite biology.
It is clear from our collective chemical proteomics studies that the pyrazolopyrimidines also interact with other Leishmania protein kinases, in particular CRK6 and CRK3, albeit with considerably lower affinities than for CRK12. Although CRK12 is undoubtedly the principal target of this compound series, we cannot rule out the possibility that underlying this mechanism of action is an element of polypharmacology. Indeed, the inhibition of secondary kinase targets may be responsible for some of the phenotypic effects observed in drug-treated parasites, such as cell cycle arrest.
Compound 7 is being advanced towards human clinical trials and is currently undergoing preclinical development. The data generated so far provide a reason to believe that compound 7 has the potential to fulfil the community target product profile (see https://www.dndi.org/ diseases-projects/leishmaniasis/tpp-vl). However, as a systematic approach to drug discovery is relatively new in this neglected disease, and there is a lack of correlation between preclinical and clinical data, there are outstanding questions that can only be answered as the compound progresses through development. 
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